newsfilter
← Latest News
GlobeNewswire·

Trevena Reports Second Quarter 2023 Results and Provides Business Update

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and